Perturbation of Rb, p53, and Brca1 or Brca2 Cooperate in Inducing Metastatic Serous Epithelial Ovarian Cancer

被引:95
|
作者
Szabova, Ludmila [1 ]
Yin, Chaoying [4 ]
Bupp, Sujata [1 ]
Guerin, Theresa M. [1 ]
Schlomer, Jerome J. [1 ]
Householder, Deborah B. [1 ]
Baran, Maureen L. [1 ]
Yi, Ming [2 ]
Song, Yurong [3 ,4 ]
Sun, Wenping [2 ]
McDunn, Jonathan E. [5 ]
Martin, Philip L. [1 ]
Van Dyke, Terry [1 ,3 ,4 ]
Difilippantonio, Simone [1 ]
机构
[1] NCI Federick, Ctr Adv Preclin Res, SAIC, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA
[2] NCI Federick, Adv Biomed Comp Ctr, SAIC, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA
[3] NCI Frederick, Mouse Canc Genet Program, Frederick, MD USA
[4] Univ N Carolina, Dept Genet, Chapel Hill, NC USA
[5] Metabolon Inc, Durham, NC USA
关键词
MOUSE MODEL; CONDITIONAL INACTIVATION; FALLOPIAN-TUBE; PERITONEAL MESOTHELIOMA; PAPILLARY CARCINOMA; DISTANT METASTASES; MUTATIONS; INDUCTION; WOMEN; P130;
D O I
10.1158/0008-5472.CAN-11-3834
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The majority of human high-grade serous epithelial ovarian cancer (SEOC) is characterized by frequent mutations in p53 and alterations in the RB and FOXM1 pathways. A subset of human SEOC harbors a combination of germline and somatic mutations as well as epigenetic dysfunction for BRCA1/2. Using Cre-conditional alleles and intrabursal induction by Cre-expressing adenovirus in genetically engineered mice, we analyzed the roles of pathway perturbations in epithelial ovarian cancer initiation and progression. Inactivation of RB-mediated tumor suppression induced surface epithelial proliferation with progression to stage I carcinoma. Additional biallelic inactivation and/or missense p53 mutation in the presence or absence of Brca1/2 caused progression to stage IV disease. As in human SEOC, mice developed peritoneal carcinomatosis, ascites, and distant metastases. Unbiased gene expression and metabolomic profiling confirmed that Rb, p53, and Brca1/2-triple mutant tumors aligned with human SEOC, and not with other intraperitoneal cancers. Together, our findings provide a novel resource for evaluating disease etiology and biomarkers, therapeutic evaluation, and improved imaging strategies in epithelial ovarian cancer. Cancer Res; 72(16); 4141-53. (C) 2012 AACR.
引用
收藏
页码:4141 / 4153
页数:13
相关论文
共 50 条
  • [31] BRCA1 and BRCA2 in breast cancer
    Lee, WH
    Boyer, TG
    LANCET, 2001, : S5 - S5
  • [32] BRCA1 and BRCA2 in breast cancer
    Xiaohong Yang
    Marc E. Lippman
    Breast Cancer Research and Treatment, 1999, 54 : 1 - 10
  • [34] Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer
    Paik, E. Sun
    Heo, Eun Jin
    Choi, Chel Hun
    Kim, Jae-Hoon
    Kim, Jae-Weon
    Kim, Yong-Man
    Park, Sang-Yoon
    Lee, Jeong-Won
    Kim, Jong-Won
    Kim, Byoung-Gie
    CANCER SCIENCE, 2021, 112 (12) : 5055 - 5067
  • [35] Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
    Bolton, Kelly L.
    Chenevix-Trench, Georgia
    Goh, Cindy
    Sadetzki, Siegal
    Ramus, Susan J.
    Karlan, Beth Y.
    Lambrechts, Diether
    Despierre, Evelyn
    Barrowdale, Daniel
    McGuffog, Lesley
    Healey, Sue
    Easton, Douglas F.
    Sinilnikova, Olga
    Benitez, Javier
    Garcia, Maria J.
    Neuhausen, Susan
    Gail, Mitchell H.
    Hartge, Patricia
    Peock, Susan
    Frost, Debra
    Evans, Gareth
    Eeles, Rosalind
    Godwin, Andrew K.
    Daly, Mary B.
    Kwong, Ava
    Ma, Edmond S. K.
    Lazaro, Conxi
    Blanco, Ignacio
    Montagna, Marco
    D'Andrea, Emma
    Nicoletto, Maria Ornella
    Johnatty, Sharon E.
    Krueger, Susanne
    Jensen, Allan
    Hogdall, Estrid
    Goode, Ellen L.
    Fridley, Brooke L.
    Loud, Jennifer T.
    Greene, Mark H.
    Mai, Phuong L.
    Chetrit, Angela
    Lubin, Flora
    Hirsh-Yechezkel, Galit
    Glendon, Gord
    Andrulis, Irene L.
    Toland, Amanda E.
    Senter, Leigha
    Gore, Martin E.
    Gourley, Charlie
    Michie, Caroline O.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 382 - 390
  • [36] Association between BRCA1 and BRCA2 mutations and Survival in women with invasive epithelial Ovarian cancer
    Bremer, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (11) : 1057 - 1058
  • [37] Frequency of BRCA1 and BRCA2 mutations in tumors of patients with epithelial ovarian cncer
    Dann, R. Byler
    DeLoia, J.
    Timms, K.
    Zorn, K.
    Potter, J.
    Flake, D.
    Krivak, T.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S116 - S116
  • [38] High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer
    T. Yu. Smirnova
    N. I. Pospekhova
    L. N. Lyubchenko
    S. A. Tjulandin
    R. F. Gar’kavtseva
    E. K. Ginter
    A. V. Karpukhin
    Bulletin of Experimental Biology and Medicine, 2007, 144 : 83 - 85
  • [39] High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer
    Smirnova, T. Yu.
    Pospekhova, N. I.
    Lyubchenko, L. N.
    Tjulandin, S. A.
    Gar'kavtseva, R. F.
    Ginter, E. K.
    Karpukhin, A. V.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2007, 144 (01) : 83 - 85
  • [40] Hereditary breast/ovarian cancer families: beyond BRCA1 and BRCA2
    Fragoso, S.
    Santos, S.
    Mira, B.
    Machado, P.
    Luis, A.
    Clara, A.
    Opiniao, A.
    Bento, S.
    Miguel, I.
    Rodrigues, P.
    Parreira, J.
    Simoes, C.
    Vaz, F.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 568 - 568